(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Step by step instructions to Boost the Eco-friendliness of Your Smash 1500. - 2Flourishing in Retirement: Individual Accounts of Post-Vocation Satisfaction
- 3The Most Important Crossroads in Olympic History
- 4Archaeologists uncover details about the Hjortspring boat's origins
- 5An Extended period of Voyaging Carefully: the World with Reason
- The race is on to turn your body into a GLP-1 factory
- King Charles shares cancer treatment update, says it's a 'personal blessing'
- This Week In Space podcast: Episode 188 — A New NASA Leader Rises?
- A Republican elected governor in California? It's not as far-fetched as it sounds.
- A Manual for SUVs with Less Noteworthy Gas Mileage
- The most effective method to Pick the Right Material Organization: Your Definitive Aide
- The most effective method to Distinguish the Best Material Organization in Your Space
- Famous Rough terrain Vehicles for 2024
- December's overlooked meteor shower peaks next week — will the Ursids surprise us?
